Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Galecto's share price for the quarter that ended in Sep. 2024 was $12.15. Galecto's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 1.25 Mil. Therefore, Galecto's market cap for the quarter that ended in Sep. 2024 was $15.23 Mil.
Galecto's quarterly market cap
declined
from Mar. 2024 ($21.15 Mil) to Jun. 2024 ($12.86 Mil) but then
increased
from Jun. 2024 ($12.86 Mil) to Sep. 2024 ($15.23 Mil).
Galecto's annual market cap
declined
from Dec. 2021 ($76.54 Mil) to Dec. 2022 ($29.50 Mil) and
declined
from Dec. 2022 ($29.50 Mil) to Dec. 2023 ($19.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Galecto's Enterprise Value for Today is $-12.96 Mil.
Galecto Market Cap Historical Data
The historical data trend for Galecto's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galecto's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galecto's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galecto's Market Cap distribution charts can be found below:
* The bar in red indicates where Galecto's Market Cap falls into.
Galecto Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Galecto's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galecto (NAS:GLTO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Galecto Market Cap Related Terms
Thank you for viewing the detailed overview of Galecto's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLTO has been successfully added to your 